**Supplementary Table 1:** Intraocular inflammation cases in brolucizumab 6 mg-treated Japanese eyes with PCV.

| Pt # | Adverse Event as reported (preferred term) | AE start (day) | Duration (days) | Other adverse events as reported (preferred term) | Treatment for IOI (Days administered) | Action taken with study drug | Latest BCVA vs BL | As noted by the SRC | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | Inflammation | Vasculitis | Occlusive |
| 1 | Iritis | 29 | 29 | - | No medications for IOI administered | Patient continued on treatment and completed study | 50 (+10L) | Yes probable | No | No |
| 2 | Uveitis | 51 | 287 | - | Top Betamethasone (85-106; 183-309), Top Fluorometholone (106-168), IO Dexamethasone (184), IO Triamcinolone (148 and 192) | Drug withdrawn (last injection Day 120) | 75 (+16L) | Yes | Yes | No |
| 3 | Iritis | 50 | 183 | Cataract aggravated (Cataract) | Top Levofloxacin (54-63), Top Bromfenac (57-81; 84-141), Top Betamethasone (84-141), Subconj Dexamethasone (92), Top Aciclovir (100-172) | Drug withdrawn (last injection Day 57) | 52 (-4L) | Yes | Yes | No |
| 4 | Uveitis | 12 | 214 | Branch retinal artery occlusion (Retinal artery occlusion) | Top Moxifloxacin (26-33), Top Betamethasone (26-81; 141-166), Top Fluorometholone (82-141, 167-194; 226-365), Top Bromfenac (195-225) | Patient continued on treatment but later withdrew from study due to change in living conditions | 80 (+18L) | Yes | Yes | Yes |
| 5 | Anterior chamber inflammation | 17 | 21 | - | Top Moxifloxacin (17-37) | Patient continued on treatment and completed study | 87 (+19L) | Yes probable | Yes probable | Yes probable |
| 6 | Retinal perivascular sheathing | 167 | Ongoing at last report (Day 197) | - | No medication administered | Drug withdrawn (last injection Day 139) | 70 (0L) | Yes | Yes | No |

Medical Dictionary for Regulatory Activities Version 20.1 has been used for the reporting of adverse events. AE, adverse event; BCVA, best corrected visual acuity; BL, baseline; IOI, intraocular inflammation; L, letters; SRC, Safety Review Committee; Top, topical.



Ogura Y, *et al. Br J Ophthalmol* 2022; 106:994–999. doi: 10.1136/bjophthalmol-2021-319090

**Supplementary Figure S1:** HAWK study design




q8w, every 8 weeks; q12w, every 12 weeks.